| 75.69 -0.96 (-1.25%) | 07-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 92.45 | 1-year : | 107.98 |
| Resists | First : | 79.15 | Second : | 92.45 |
| Pivot price | 73.26  |
|||
| Supports | First : | 71.82 | Second : | 67.3 |
| MAs | MA(5) : | 75.43 |
MA(20) : | 72.27 |
| MA(100) : | 67.92 |
MA(250) : | 69.46 |
|
| MACD | MACD : | 1.4 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 79.9 |
D(3) : | 76.9 |
| RSI | RSI(14): 56.6 |
|||
| 52-week | High : | 89.98 | Low : | 54.11 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DXCM ] has closed below upper band by 28.9%. Bollinger Bands are 16.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 77.23 - 77.67 | 77.67 - 78.15 |
| Low: | 74.43 - 74.92 | 74.92 - 75.45 |
| Close: | 74.77 - 75.62 | 75.62 - 76.54 |
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Mon, 20 Jul 2026
Dexcom (NASDAQ: DXCM) executive plans 26,756-share stock sale - Stock Titan
Sat, 18 Jul 2026
DexCom (DXCM) Back In Focus As Canada Approval Tests Its Valuation - Sahm
Thu, 16 Jul 2026
DexCom, Inc.’s stock price soars to $77.98, marking a remarkable 7.22% increase - Smartkarma
Thu, 16 Jul 2026
DEXCOM INC (DXCM) EVP reports 1,700-share planned stock sale in Form 4 - Stock Titan
Thu, 16 Jul 2026
DexCom Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Thu, 16 Jul 2026
Why DexCom Inc (DXCM) Is Set to Outperform the Market: Insights into Financial Growth and Competitive Advantage - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 386 (M) |
| Shares Float | 385 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 102.1 (%) |
| Shares Short | 18,110 (K) |
| Shares Short P.Month | 17,390 (K) |
| EPS | 2.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.65 |
| Profit Margin | 19.3 % |
| Operating Margin | 21.4 % |
| Return on Assets (ttm) | 9.6 % |
| Return on Equity (ttm) | 35.6 % |
| Qtrly Rev. Growth | 15 % |
| Gross Profit (p.s.) | 7.67 |
| Sales Per Share | 12.49 |
| EBITDA (p.s.) | 3.34 |
| Qtrly Earnings Growth | 92.1 % |
| Operating Cash Flow | 1,780 (M) |
| Levered Free Cash Flow | 1,060 (M) |
| PE Ratio | 32.48 |
| PEG Ratio | 1.3 |
| Price to Book value | 9.88 |
| Price to Sales | 6.05 |
| Price to Cash Flow | 16.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|